PCN121 LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2- OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA
Autor: | H. Sandhu, A. Berardi |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
medicine.medical_specialty Everolimus Cost effectiveness business.industry Health Policy Public Health Environmental and Occupational Health Checkmate medicine.disease Maturity (finance) Term (time) Second line Renal cell carcinoma Internal medicine medicine Nivolumab business medicine.drug |
Zdroj: | Value in Health. 23:S44 |
ISSN: | 1098-3015 |
Databáze: | OpenAIRE |
Externí odkaz: |